SAINT-PRIEST, FRANCE / ACCESSWIRE / April 24, 2019 / Biom'up (the « Company »), specializing in surgical hemostasis, announced today that the U.S. Food and Drug Administration (FDA) approved the IDE ...

Taking the occasional loss comes part and parcel with investing on the stock market. And there’s no doubt that Biom’Up S.A. (EPA:BUP) stock has had a really bad year. To wit the share price is down 61 ...

SAINT-PRIEST, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the adoption of the interim consolidated financial statements for the period ended June 30, 2018 by the Board of Directors on ...

SAINT-PRIEST, France--(BUSINESS WIRE)--Regulatory News: Biom’up (Paris:BUP)(the “Company”), a specialist in surgical hemostasis, announces today the completion of the 2018 scale-up of its ...

SAINT-PRIEST, France, March 26, 2018 (GLOBE NEWSWIRE) -- Biom’up, specialist of surgical hemostasis, today announced the appointment, effective May 2, 2018, of Thierry Darnis as Global Vice President ...

Biom’up, a developer of hemostatic products, has named Stéphanie Boileau-Canu as chief financial officer and Emmanuel Zylber as chief scientific officer. Biom’up is backed by Athyrium Capital.

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! A look at the shareholders of Biom'Up S.A. (EPA:BUP) can tell us which group ...

Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning catastrophes, wherever possible. So spare a thought for the long term shareholders ...

Explore the BIOM UP stock price history with detailed daily historical prices, including open, high, low, close, and volume data. Review past trends, identify key price levels, and find the highest ...